Drug Information

Drug General Information
Drug ID
D0D3TX
Former ID
DNCL001975
Drug Name
EVP-6124
Drug Type
Small molecular drug
Indication Mild to moderate alzheimer disease; Schizophrenia [ICD9: 331, 295; ICD10:G30, F20] Phase 3 [524557]
Company
EnVivo Pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C16H17ClN2OS
Canonical SMILES
C1CN2CCC1C(C2)NC(=O)C3=CC4=C(S3)C(=CC=C4)Cl
InChI
1S/C16H17ClN2OS/c17-12-3-1-2-11-8-14(21-15(11)12)16(20)18-13-9-19-6-4-10(13)5-7-19/h1-3,8,10,13H,4-7,9H2,(H,18,20)/t13-/m0/s1
InChIKey
SSRDSYXGYPJKRR-ZDUSSCGKSA-N
PubChem Compound ID
46196517
PubChem Substance ID
96050357, 120464478, 140815172, 160647552, 162108893, 163330298, 163342279, 163620874, 178103508, 184812353, 198975916, 202033139, 224745217, 227030966, 243657139, 252478817
Target and Pathway
Target(s) Neuronal acetylcholine receptor protein, alpha-7 chain Target Info Modulator [532624]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Cholinergic synapse
Nicotine addiction
Chemical carcinogenesis
PANTHER Pathway Alzheimer disease-amyloid secretase pathway
Nicotinic acetylcholine receptor signaling pathway
Reactome Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
WikiPathways SIDS Susceptibility Pathways
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
References
Ref 524557ClinicalTrials.gov (NCT02004392) Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025. U.S. National Institutes of Health.
Ref 532624Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.